Company intelligence / Profile preview

Bacthera

Ownership: Private
Employees: ~180
Development stage: Other

Overview

Bacthera provided end-to-end CDMO services dedicated to live biotherapeutic products, supporting development from preclinical through commercial manufacturing. The company handled over 30 LBP batches annually and supported both clinical and commercial supply chains for clients. It was recognized for expertise with diverse microbial strains under GMP conditions but has entered liquidation as of mid–2024.

Therapeutic areas: Cardiovascular
Modalities: Live biotherapeutic product therapyMicrobial therapy
Industry: Contract Manufacturing Organization

Partnerships

BioMe Inc. (collaboration on BM109 candidate for cardiorenal diseases)

Beyond the preview

Go deeper on Bacthera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacthera.